Sotera Health Company SHC
Nov 3, 2026, 3:45 PM EST
- YTD
- -8.76%
- 1 year
- -3.10%
- Market cap
- 4.58B
- Revenue (ttm)
- 1.22B
- Profit margin
- 13.44%
- EPS (ttm)
- 0.57
- Shares out
- 285.37M
- P/E ratio
- 28.16
- Forward P/E
- 16.50
- YTD return
- -8.76%
- 1-year return
- -3.10%
- Volume
- 3.64M
- Avg volume
- 2.30M
- Open
- 17.09
- Previous close
- 17.74
- Day's range
- 16.03 – 17.28
- 52-week range
- 13.09 – 19.85
- Beta
- 1.93
- Analysts
- Buy
- Price target
- 22.61 (+40.5%)
- Earnings date
- Nov 3, 2026
YTD -1.49 (-8.42%)
Key statistics
- Enterprise value
- 7.09B
- PEG ratio
- 1.31
- Price / sales
- 4.16
- Price / book
- 7.60
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 9.20%
- Free cash flow
- 153.97M
- Total cash
- 356.95M
- Total debt
- 2.27B
- Return on equity
- 27.78%
- Short % of float
- 6.51%
- 50-day average
- 18.52
- 200-day average
- 17.00
Analyst view
Consensus: buy
- Target (low)
- 17.00
- Target (mean)
- 22.61
- Target (high)
- 25.00
- Strong buy3
- Buy5
- Hold1
- Sell0
- Strong sell1
Next earnings
Nov 3, 2026
Expected Nov 3, 2026. Consensus EPS estimate 0.26864.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 3, 2026 | Sep 30, 2026 | 0.2687 | — | — | — |
| Aug 6, 2026 | Jun 30, 2026 | 0.2389 | 0.26 | +0.02 | +8.83% |
| May 5, 2026 | Mar 31, 2026 | 0.17 | 0.18 | +0.01 | +5.88% |
| Feb 24, 2026 | Dec 31, 2025 | 0.24 | 0.26 | +0.02 | +8.33% |
| Nov 4, 2025 | Sep 30, 2025 | 0.22 | 0.26 | +0.04 | +18.18% |
| Aug 8, 2025 | Jun 30, 2025 | 0.17 | 0.20 | +0.03 | +17.65% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 14, 2026 | JP Morgan | down | Neutral | Underweight |
| Aug 7, 2026 | Citigroup | main | Buy | Buy |
| Aug 7, 2026 | Barclays | main | Overweight | Overweight |
| Aug 7, 2026 | Piper Sandler | reit | Overweight | Overweight |
| Aug 7, 2026 | JP Morgan | main | Neutral | Neutral |
| Jun 24, 2026 | Barclays | main | Overweight | Overweight |
About Sotera Health Company
Sotera Health Company provides sterilization solutions, lab testing, and advisory services for the healthcare industry in the United States, Canada, Europe, and internationally. The company operates through three segments: Sterigenics, Nordion, and Nelson Labs. The Sterigenics segment offers outsourced terminal sterilization and irradiation services using gamma irradiation, ethylene oxide processing, and electron beam irradiation technologies for medical devices, pharmaceutical, and food safety and advanced applications markets. The Nordion segment provides Cobalt-60 used in the sterilization and irradiation processes for the medical device, pharmaceutical, food safety, and high-performance materials industries, as well as in the treatment of cancer. It also offers gamma irradiation systems. The Nelson Labs segment provides outsourced microbiological and analytical chemistry testing and advisory services for the medical device and pharmaceutical industries. The company was formerly known as Sotera Health Topco, Inc. and changed its name to Sotera Health Company in October 2020. Sotera Health Company was incorporated in 2015 and is headquartered in Broadview Heights, Ohio.
- Sector
- Healthcare
- Industry
- Diagnostics & Research
- Country
- United States
- Website
- soterahealth.com
News
What Sotera Health (SHC) Said on Its Q3 Earnings Call 
Here's What Key Metrics Tell Us About Sotera Health (SHC) Q3 Earnings 
Sotera Health Q3 2026 Earnings Call Transcript 
Sotera Health Company (SHC) Beats Q3 Earnings and Revenue Estimates 
Sotera Health Q3 Adj. EPS $0.29 Beats $0.27 Estimate, Sales $324.886M Beat $319.774M Estimate 
Sotera Health Affirms FY2026 Adj EPS Guidance of $0.95-$1.01 vs $0.98 Est; Lowers FY2026 Sales Guidance from $1.236B-$1.254B to $1.233B-$1.250B vs $1.247B Est 
Sotera Health Reports Solid Third-Quarter and Year-to-Date 2026 Results 
Sotera Health Announces Third-Quarter 2026 Earnings Release Date 
JP Morgan Downgrades Sotera Health to Underweight, Announces $17 Price Target 
Transcript: Sotera Health Q2 2026 Earnings Conference Call
Your note
Sign in to keep a note on SHC — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| CUNNINGHAM SEAN LAURENCE | Director | Stock Award(Grant) | May 21, 2026 | 95,751 |
| DIMITRIEF ALEXANDER | General Counsel | Conversion of Exercise of derivative security | Mar 1, 2026 | 319,981 |
| KLEE ANN R | Director | Stock Award(Grant) | May 21, 2026 | 140,926 |
| LYONS JONATHAN M | Chief Financial Officer | Stock Award(Grant) | Mar 1, 2026 | 228,620 |
| NEARY JAMES C | Director | Stock Award(Grant) | May 21, 2026 | 95,751 |
| PETRAS MICHAEL B. JR. | Officer and Director | Sale | Aug 16, 2026 | 0 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Sessa Capital IM, L.P. | 9.48% | 27,050,000 | 479.87M | Jun 29, 2026 |
| Darsana Capital Partners, LP | 9.46% | 27,000,000 | 478.98M | Jun 29, 2026 |
| Blackrock Inc. | 8.46% | 24,148,424 | 428.39M | Jun 29, 2026 |
| Sculptor Capital LP | 8.41% | 24,000,000 | 425.76M | Jun 29, 2026 |
| Sachem Head Capital Management, LP | 5.45% | 15,560,000 | 276.03M | Jun 29, 2026 |
| Vanguard Capital Management LLC | 4.26% | 12,170,699 | 215.91M | Jun 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| iShares Trust-iShares Core S&P Mid-Cap ETF | 3.56% | 10,168,349 | 180.39M | Sep 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 3.02% | 8,614,655 | 152.82M | Jun 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Small-Cap Index Fund | 2.18% | 6,215,762 | 110.27M | Jun 29, 2026 |
| JANUS INVESTMENT FUND-Janus Henderson Contrarian Fund | 2.05% | 5,853,280 | 103.84M | Jun 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Small-Cap Growth Index Fund | 1.25% | 3,578,222 | 63.48M | Jun 29, 2026 |
| T. Rowe Price Small-Cap Stock Fund, Inc. | 1.09% | 3,120,870 | 55.36M | Jun 29, 2026 |